

## aMoon portfolio:

- [MiNA Therapeutics](#), London, UK: Harnessing an innate mechanism of gene activation, MiNA Therapeutics' platform enables the development of new medicines that restore normal function to patients' cells.
- [Aummune](#), Israel: Aummune is a pre-clinical cancer therapeutics company which is developing a breakthrough de novo and rapid process, personalized to patient's specific disease parameters at each stage of the therapeutic pathway.

## Others:

- [Sterna-Biologicals](#), Marburg, Germany: Aclinical-stage immunology company developing novel treatments for chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and ulcerative colitis.
- [SILENSEED](#), Israel: Silenseed is a clinical stage biopharmaceutical company that is developing proprietary RNA interference (RNAi)-based cancer drugs and delivery systems designed to effectively penetrate and treat malignant solid tumors.
- [Acticor Biotech](#), Paris, France: Acticor Biotech is a clinical stage biotechnology company, founded in 2013 as a spin-off of INSERM, developing an innovative drug for the treatment of acute thrombotic diseases, including the acute phase of ischemic stroke.
- [Cardior Pharmaceuticals](#), Hanover, Germany: Cardior Pharmaceuticals is a biopharmaceutical company founded in 2016 as spin-off from Medical School Hannover (MHH). The company is focused on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as innovative medicines for patients with various forms of heart failure. Within only two years Cardior Pharmaceuticals has advanced from research to clinical stage.
- [Dynacure](#), Illkirch-Graffenstaden, France: A biotechnology company developing new treatments for patients affected by serious orphan disorders. In its first drug discovery program, Dynacure is focusing on Centronuclear Myopathies (CNM), a rare, debilitating disease affecting children and young adults.
- [Silence Therapeutics](#), London, UK: Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence is currently focused on developing siRNA molecules for the potential treatment of cardiovascular disease, rare diseases such as iron overload disorders, and complement-mediated disorders.
- [CureVac](#), Tübingen, Germany: The company is developing a completely new class of drugs based on the messenger RNA (mRNA). The basic principle is the use of this molecule as a data carrier for information, with the help of which the body itself can produce its own active substances to combat various diseases.
- [BioNTech](#), Mainz, Germany: The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing

multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.

- [eTheRNA](#), Niel, BELGIUM: a clinical-stage company developing innovative immunotherapies from its proprietary mRNA TriMix platform. eTheRNA was established in January 2013 as a spin-off from the VUB university in Belgium and is developing products for the treatment of cancer and infectious disease.